Lymph Node Dissection and Postoperative Complications After Lung Cancer Resection - Summary - MDSpire

Lymph Node Dissection and Postoperative Complications After Lung Cancer Resection

  • By

  • Isheeta Madeka

  • Khaled Noueihed

  • Jacob Woodroof

  • Shale Mack

  • Hamza Rshaidat

  • Gregory L. Whitehorn

  • Sneha Alaparthi

  • Scott H. Koeneman

  • Tyler R. Grenda

  • Nathaniel R. Evans

  • Olugbenga T. Okusanya

  • June 1, 2026

  • 0 min

Share

Objective:

To evaluate whether satisfying the 3 + 1 lymph node sampling criteria is associated with increased postoperative complications in patients undergoing surgical resection for NSCLC.

Key Findings:
  • Out of 28,439 patients, 66.6% satisfied the 3 + 1 lymph node sampling criteria.
  • Patients meeting the 3 + 1 criteria were more likely to receive preoperative pulmonary function tests and undergo robotic surgery.
  • No significant differences in postoperative complications were found between the two groups.
Interpretation:

Limitations:
  • The study is retrospective and may be subject to selection bias.
  • Data on certain variables, such as duration of operation and length of stay, were not included in the propensity match.
Conclusion:

Satisfying the 3 + 1 lymph node sampling criteria does not appear to increase postoperative complications in patients undergoing surgical resection for NSCLC.

Original Source(s)

Lymph Node Dissection and Postoperative Complications After Lung Cancer Resection

  • by Isheeta Madeka, Khaled Noueihed, Jacob Woodroof, Shale Mack, Hamza Rshaidat, Gregory L. Whitehorn, Sneha Alaparthi, Scott H. Koeneman, Tyler R. Grenda, Nathaniel R. Evans, Olugbenga T. Okusanya

  • June 1, 2026

Related Content

From monoclonals to bispecific T cell engagers: the evolving antibody-based therapy landscape in acute myeloid leukemia

Case Report: A rare triad of neoplasms: navigating synchronous accessory breast cancer, papillary thyroid carcinoma, and inflammatory nasal papilloma

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry